Grandeur Peak Global Advisors LLC Invests $16.43 Million in AtriCure, Inc. $ATRC

Grandeur Peak Global Advisors LLC acquired a new position in AtriCure, Inc. (NASDAQ:ATRC) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 587,399 shares of the medical device company’s stock, valued at approximately $16,435,000. AtriCure comprises about 3.3% of Grandeur Peak Global Advisors LLC’s investment portfolio, making the stock its 8th largest holding.

A number of other hedge funds have also recently modified their holdings of the business. Geneos Wealth Management Inc. bought a new stake in shares of AtriCure during the 2nd quarter worth approximately $37,000. Smartleaf Asset Management LLC lifted its position in shares of AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares during the last quarter. Harbor Investment Advisory LLC purchased a new stake in shares of AtriCure during the second quarter valued at $40,000. Allworth Financial LP bought a new position in shares of AtriCure in the second quarter worth about $43,000. Finally, Fifth Third Bancorp purchased a new position in AtriCure in the 1st quarter worth about $51,000. Institutional investors own 99.11% of the company’s stock.

AtriCure Stock Up 2.3%

Shares of AtriCure stock opened at $49.27 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. AtriCure, Inc. has a 1 year low of $25.36 and a 1 year high of $49.88. The firm’s 50-day moving average is $37.50 and its two-hundred day moving average is $32.14. The stock has a market cap of $2.51 billion, a price-to-earnings ratio of 234.63 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. During the same quarter in the previous year, the business posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts expect that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

ATRC has been the subject of several research reports. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Piper Sandler raised their target price on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday. Wall Street Zen lowered AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. BTIG Research increased their price objective on AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Zacks Research cut AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $49.89.

Insider Activity at AtriCure

In related news, Director Karen Prange sold 3,564 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total value of $138,283.20. Following the completion of the transaction, the director owned 22,809 shares of the company’s stock, valued at $884,989.20. The trade was a 13.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Vinayak Doraiswamy sold 6,000 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total value of $233,280.00. Following the sale, the insider owned 86,511 shares of the company’s stock, valued at approximately $3,363,547.68. This represents a 6.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 53,616 shares of company stock valued at $2,149,994 over the last quarter. 4.00% of the stock is owned by insiders.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.